Drug-maker Sun Pharmaceutical saw a 46 per cent dip in its net profit, in the July-September quarter, because of Rs 584 crore set aside towards potential damages it may have to pay in a patent infringement case on heart-burn drug Protonix, in the United States.
But the company’s businesses across India, the US and in markets in the rest of the world continue to demonstrate good growth, in line with expectations, said Dilip Shanghvi, Managing Director, in a company statement.
Sun’s branded generic sales in India at Rs 810 crore, were up 15 per cent over Q2 last year, the company said. The company’s US finished dosage sale, at $244 million, grew 38 per cent (in dollar terms) over Q2 last year and its international finished drug sales, at $68 million, were up 21 per cent, the company said. Sun Pharma shares were marginally down on the BSE, at Rs 696, on Thursday.